Drug & intervention

pasireotide

RxCUI 1364105

Clinical trials4

Recruiting0

Related conditions16

Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

4 shown

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored StudiesNCT01794793 · 2013-06-10

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate CancerNCT01468532 · 2011-10-01

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate CancerNCT01313559 · 2011-06-01

Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast CancerNCT01356862 · 2010-09-01

Conditions being studied

Prostate Cancer2 Acromegaly1 Adenocarcinoma of the Prostate1 Breast Cancer1 Castrate Resistant Prostate Cancer1 Chemotherapy Naive Prostate Cancer1 Cushing's Disease1 Dumping Syndrome1 Ectopic ACTH Secreting (EAS) Tumors1 Hormone-resistant Prostate Cancer1 Melanoma Negative for bRAF1 Melanoma Negative for nRAS1 Neuroendocrine Tumors1 Pituitary Tumors1 Recurrent Prostate Cancer1 Stage IV Prostate Cancer1

Research locations

AngersFrance1 AnkaraTurkey (Türkiye)1 Ann ArborMichigan, United States1 BangkokThailand1 BarcelonaSpain1 BerlinGermany1 BronFrance1 BrusselsBelgium1 BucharestRomania1 BudapestHungary1 DetroitMichigan, United States1 GdanskPoland1

Leading sponsors

Alliance Pour La Recherche en Cancerologie1 Barbara Ann Karmanos Cancer Institute1 RECORDATI GROUP1 Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.